Suppr超能文献

一种将生物识别标签附加到内源性突变 Kras 等位基因末端的简便方法。

A Facile Method to Append a Bio-ID Tag to Endogenous Mutant Kras Alleles.

机构信息

Drexel University College of Medicine, Philadelphia, PA, USA.

Fox Chase Cancer Center, Philadelphia, PA, USA.

出版信息

Methods Mol Biol. 2024;2797:351-362. doi: 10.1007/978-1-0716-3822-4_25.

Abstract

KRAS mutations occur in approximately ~50% of colorectal cancers (CRCs) and are associated with poor prognosis and resistance to therapy. While these most common mutations found at amino acids G12, G13, Q61, and A146 have long been considered oncogenic drivers of CRC, emerging clinical data suggest that each mutation may possess different biological functions, resulting in varying consequences in oncogenesis. Currently, the mechanistic underpinnings associated with each allelic variation remain unclear. Elucidating the unique effectors of each KRAS mutant could both increase the understanding of KRAS biology and provide a basis for allele-specific therapeutic opportunities. Biotinylation identification (BioID) is a method to label and identify proteins located in proximity of a protein of interest. These proteins are captured through the strong interaction between the biotin label and streptavidin bead and subsequently identified by mass spectrometry. Here, we developed a protocol using CRISPR-mediated gene editing to generate endogenous BioID-tagged Kras and Kras isogenic murine colon epithelial cell lines to identify unique protein proximity partners by BioID.

摘要

KRAS 突变约发生于 50%的结直肠癌(CRC)中,与不良预后和治疗耐药相关。虽然最常见的突变发生在氨基酸 G12、G13、Q61 和 A146,但长期以来一直被认为是 CRC 的致癌驱动因素,新兴的临床数据表明,每种突变可能具有不同的生物学功能,从而导致致癌作用的不同后果。目前,与每种等位基因变异相关的机制基础仍不清楚。阐明每个 KRAS 突变体的独特效应因子既能增加对 KRAS 生物学的理解,又能为等位基因特异性治疗机会提供基础。生物素标记鉴定(BioID)是一种标记和鉴定与感兴趣的蛋白质接近的蛋白质的方法。这些蛋白质通过生物素标记和链霉亲和素珠之间的强相互作用被捕获,然后通过质谱法进行鉴定。在这里,我们开发了一种使用 CRISPR 介导的基因编辑来生成内源性 BioID 标记的 Kras 和 Kras 同基因鼠结肠上皮细胞系的方案,通过 BioID 来鉴定独特的蛋白质邻近伙伴。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验